Copyright 2010 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2010
Panitumumab is 1 of 2 monoclonal antibody (mAb) epidermal growth factor receptor inhibitors (EGFRIs) approved by the US Food and Drug Administration (FDA) and increasingly used to treat metastatic colorectal carcinoma. The cutaneous adverse effects of EGFRIs include papulopustular eruption, xerosis, pruritus, paronychia, hair growth abnormalities, telangiectasia, and others.1 Adverse effects of panitumumab have been well documented in the oncology literature but have received less attention in dermatologic journals. We herein report a case of a severe papulopustular eruption associated with panitumumab treatment.
Korman JB, Ward DB, Maize JC. Papulopustular Eruption Associated With Panitumumab. Arch Dermatol. 2010;146(8):918-935. doi:10.1001/archdermatol.2010.170